Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
Authors
Keywords
-
Journal
TUMORI
Volume 103, Issue 5, Pages 405-421
Publisher
SAGE Publications
Online
2017-05-12
DOI
10.5301/tj.5000625
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
- (2017) Martin Rao et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- TumorMGMTpromoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer
- (2016) A. Amatu et al. ANNALS OF ONCOLOGY
- CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency
- (2016) B. Lo et al. BLOOD
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis
- (2016) O. Abdel-Rahman et al. CLINICAL ONCOLOGY
- Endocrinological side-effects of immune checkpoint inhibitors
- (2016) Francesco Torino et al. CURRENT OPINION IN ONCOLOGY
- Ocular and orbital side-effects of checkpoint inhibitors
- (2016) Joëlle Antoun et al. CURRENT OPINION IN ONCOLOGY
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- (2016) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- (2016) Lars Hofmann et al. EUROPEAN JOURNAL OF CANCER
- A Case of Bilateral Uveitis and Papillitis in a Patient Treated with Pembrolizumab
- (2016) Khawla Abu Samra et al. EUROPEAN JOURNAL OF OPHTHALMOLOGY
- Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
- (2016) Edurne Arriola et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus
- (2016) Kyoko Inadomi et al. MEDICINE
- Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma
- (2016) Benjamin Y. Kong et al. MELANOMA RESEARCH
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment
- (2016) Guillermo de Velasco et al. Arthritis & Rheumatology
- Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy
- (2016) A. R. Greenplate et al. Cancer Immunology Research
- Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer
- (2016) M. Nishino et al. Cancer Immunology Research
- Ipilimumab-induced colitis: experience from a tertiary referral center
- (2016) Anthony O’Connor et al. Therapeutic Advances in Gastroenterology
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells
- (2015) S. Kanameishi et al. ANNALS OF ONCOLOGY
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
- (2015) Juan Martin-Liberal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Pancreatitis Secondary to Anti–Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT
- (2015) Yazan Z. Alabed et al. CLINICAL NUCLEAR MEDICINE
- Recent developments and future challenges in immune checkpoint inhibitory cancer treatment
- (2015) Bas D. Koster et al. CURRENT OPINION IN ONCOLOGY
- Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
- (2015) Caroline Gaudy et al. DIABETES CARE
- Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis
- (2015) Omar Abdel-Rahman et al. Future Oncology
- Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review
- (2015) J. Kopecky et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-induced toxicities and the gastroenterologist
- (2015) Robert Cheng et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Peripheral Neuropathy Associated With Ipilimumab
- (2015) Iyavut Thaipisuttikul et al. JOURNAL OF IMMUNOTHERAPY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer
- (2015) Aaron I. Loochtan et al. MUSCLE & NERVE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
- (2015) B. Lo et al. SCIENCE
- Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma
- (2015) Shannon K. Quirk et al. Translational Research
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
- (2015) Martina Sanlorenzo et al. JAMA Dermatology
- Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
- (2015) S. H. Tirumani et al. Cancer Immunology Research
- Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center
- (2015) Douglas B. Johnson et al. Cancer Immunology Research
- Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy
- (2015) Jennifer A. Lo et al. JAMA Oncology
- Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
- (2015) Antonio Grimaldi et al. Journal for ImmunoTherapy of Cancer
- Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease
- (2014) R. W. Stidham et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Th17 and regulatory T cell balance in autoimmune and inflammatory diseases
- (2014) Mélissa Noack et al. AUTOIMMUNITY REVIEWS
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Kidney injuries related to ipilimumab
- (2014) Hassane Izzedine et al. INVESTIGATIONAL NEW DRUGS
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab in patients with cancer and the management of dermatologic adverse events
- (2014) Mario E. Lacouture et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series
- (2014) Sowmya Ravi et al. Journal for ImmunoTherapy of Cancer
- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
- (2013) Jeffrey S. Weber et al. CANCER
- Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
- (2013) Igor Z. Barjaktarevic et al. CHEST
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
- (2013) Francesco Torino et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Ipilimumab associated hepatitis: imaging and clinicopathologic findings
- (2013) Kyung Won Kim et al. INVESTIGATIONAL NEW DRUGS
- Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
- (2013) Salvatore Maria Corsello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Ipilimumab-induced Perforating Colitis
- (2013) Kisha A. Mitchell et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab Administration in Patients With Advanced Melanoma and Hepatitis B and C
- (2013) Anupa Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
- (2013) Kira Minkis et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Association Between Ipilimumab and Celiac Disease
- (2013) Nicole M. Gentile et al. MAYO CLINIC PROCEEDINGS
- Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy
- (2013) Sofya Pintova et al. MELANOMA RESEARCH
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab and Its Toxicities: A Multidisciplinary Approach
- (2013) L. A. Fecher et al. ONCOLOGIST
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
- (2013) David Gardiner et al. PLoS One
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
- (2012) David E. Kleiner et al. DIGESTIVE DISEASES AND SCIENCES
- Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
- (2012) Grégoire Berthod et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A Severe Case of Ipilimumab-Induced Guillain-Barré Syndrome Revealed by an Occlusive Enteric Neuropathy
- (2012) Caroline Gaudy-Marqueste et al. JOURNAL OF IMMUNOTHERAPY
- Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
- (2012) Sebastian G. Bernardo et al. MELANOMA RESEARCH
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of the PD-1 pathway in autoimmunity and peripheral tolerance
- (2011) Brian T. Fife et al. Annals of the New York Academy of Sciences
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
- (2011) Katarzyna D. Chmiel et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission
- (2011) Wouter V. Vogel et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Hemophilia A Induced by Ipilimumab
- (2011) Julie Delyon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma
- (2011) S Ahmad et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2
- (2010) S. Huber et al. BLOOD
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Yin-Yang of costimulation: crucial controls of immune tolerance and function
- (2009) Roza I. Nurieva et al. IMMUNOLOGICAL REVIEWS
- Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)
- (2009) Mojtaba Akhtari et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions
- (2009) O Akbari et al. Mucosal Immunology
- Anti-CTLA4 Antibody–Induced Lupus Nephritis
- (2009) Fouad Fadel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
- (2009) Troy Dillard et al. Pituitary
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
- (2008) Ilyssa O. Gordon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
- (2008) A. Eckert et al. DERMATOLOGY
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More